Recombinant Biotinylated Human Growth Hormone R, ultra sensitivity (primary amine labeling), His-Tag, 50 µg

Background
Growth hormone receptor (GHR) is also known as somatotropin receptor, growth hormone-binding protein (GHBR), which belongs to the type I cytokine receptor family or Type 1 subfamily. GHR contains one fibronectin type-III domain. GHR / GHBR is expressed in various tissues with high expression in liver and skeletal muscle. The soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. GHR is receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway. The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.

Source
Recombinant MABSol® Biotinylated Human GHR, His Tag, ultra sensitivity (primary amine labeling) (GHR-H8222) is expressed from human HEK293 cells. It contains AA Ala 27 - Tyr 264 (Accession # P10912-1). It is the biotinylated form of Human Growth Hormone R (GHR) Protein (GHR-H5222).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 29.6 kDa. The protein migrates as 40-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Bioactivity
Please refer to product data sheet.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics"
O'Shaughnessy, Gradishar, O'Regan et al
Clin Breast Cancer (2023)
(2) "Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine"
Wang, Yue, Kang et al
Cancer Biol Med (2023) 20 (4), 287-96
(3) "A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression"
Brett, Dubash, Johnson et al
JCO Precis Oncol (2023) 7, e2200532
Showing 1-3 of 8325 papers.